Compare · ANIP vs ELOX
ANIP vs ELOX
Side-by-side comparison of ANI Pharmaceuticals Inc. (ANIP) and Eloxx Pharmaceuticals Inc. (ELOX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ANIP focuses on Biotechnology: Pharmaceutical Preparations, while ELOX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- ANIP is the larger of the two at $1.61B, about 32.7x ELOX ($49.3M).
- Over the past year, ANIP is down 21.4% and ELOX is up 30.2% - ELOX leads by 51.6 points.
- ANIP has been more active in the news (6 items in the past 4 weeks vs 2 for ELOX).
- ANIP has more recent analyst coverage (14 ratings vs 7 for ELOX).
- Company
- ANI Pharmaceuticals Inc.
- Eloxx Pharmaceuticals Inc.
- Price
- $72.27+3.10%
- $13.35-5.52%
- Market cap
- $1.61B
- $49.3M
- 1M return
- -1.91%
- -28.03%
- 1Y return
- -21.38%
- +30.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 6
- 2
- Recent ratings
- 14
- 7
ANI Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Eloxx Pharmaceuticals Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Latest ANIP
- SEC Form 4 filed by ANI Pharmaceuticals Inc.
- ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting
- SVP & CFO Carey Stephen P. sold $208,050 worth of shares (2,850 units at $73.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,993 units (SEC Form 4)
- ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
- Oppenheimer initiated coverage on ANI Pharma
- ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
- PRESIDENT & CEO Lalwani Nikhil sold $383,400 worth of shares (5,400 units at $71.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 339,089 units (SEC Form 4)
- Director Thoma Jeanne sold $71,530 worth of shares (1,000 units at $71.53) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 26,762 units (SEC Form 4)
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $35,395 worth of shares (500 units at $70.79) as part of a pre-agreed trading plan, decreasing direct ownership by 0.67% to 73,924 units (SEC Form 4)
- Leerink Partners initiated coverage on ANI Pharma with a new price target
Latest ELOX
- Cantor Fitzgerald initiated coverage on Eloxx Pharmaceuticals
- SEC Form EFFECT filed by Eloxx Pharmaceuticals Inc.
- Leerink Partners initiated coverage on Eloxx Pharmaceuticals with a new price target
- SEC Form S-1 filed by Eloxx Pharmaceuticals Inc.
- Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
- Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
- SEC Form 8-K filed by Eloxx Pharmaceuticals Inc.
- SEC Form 10-Q filed by Eloxx Pharmaceuticals Inc.
- Guggenheim initiated coverage on Eloxx Pharmaceuticals with a new price target
- Large owner Domicilium Real Estate Fund Iii Lp acquired 600,000 shares (SEC Form 4)